JJKK 048

JJKK 048 is a highly selective and potent monoacylglycerol lipase (MAGL) inhibitor with IC50 values of 214 pM, 275 pM and 363 pM for human, rat, and mouse MAGL. JJKK 048 displays low cross-reactivity with other endocannabinoid targets. JJKK 048 can be used in the research of diseases such as cancer, neurodegenerative diseases, and pain[1][2].

Product Specifications

CAS Number

[1515855-97-6]

UNSPSC

12352005

Hazard Statement

H315, H319

Target

MAGL

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/JJKK_048.html

Purity

99.55

Solubility

DMSO : 33.33 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N1CCC(C(C2=CC=C(OCO3)C3=C2)C4=CC=C(OCO5)C5=C4)CC1)N6N=CN=C6

Molecular Formula

C23H22N4O5

Molecular Weight

434.44

Precautions

H315, H319

References & Citations

[1]Aaltonen N, et al. In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis- (benzo[d][1,3]dioxol-5-yl) methyl]-piperidin-1-yl} (1H-1,2,4-triazol-1-yl) methanone (JJKK-048) . J Pharmacol Exp Ther. 2016 Oct;359 (1) :62-72.|[2]Aaltonen N, et al. Piperazine and piperidine triazole ureas as ultrapotent and highly selective inhibitors of monoacylglycerol lipase. Chem Biol. 2013 Mar 21;20 (3) :379-90.